Jump Financial LLC grew its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 303.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 13,514 shares of the company’s stock after purchasing an additional 10,163 shares during the quarter. Jump Financial LLC owned 0.06% of Establishment Labs worth $1,180,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Deutsche Bank AG bought a new position in shares of Establishment Labs in the second quarter valued at $27,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Establishment Labs during the second quarter worth $29,000. Citigroup Inc. purchased a new stake in shares of Establishment Labs during the second quarter valued at $30,000. New York State Common Retirement Fund acquired a new position in shares of Establishment Labs in the 1st quarter valued at $52,000. Finally, Legal & General Group Plc purchased a new position in Establishment Labs in the 2nd quarter worth about $72,000. 60.27% of the stock is currently owned by institutional investors.
Several research analysts have recently weighed in on ESTA shares. BTIG Research reissued a “buy” rating and issued a C$90.00 target price on shares of Establishment Labs in a research report on Monday, August 23rd. The Goldman Sachs Group upped their price target on Establishment Labs from $68.00 to $78.00 and gave the company a “neutral” rating in a research report on Tuesday, August 3rd. Jefferies Financial Group initiated coverage on Establishment Labs in a report on Friday, July 30th. They issued a “buy” rating and a $90.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Monday, September 6th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Establishment Labs has an average rating of “Buy” and a consensus target price of $84.60.
ESTA opened at $78.39 on Thursday. The company has a quick ratio of 3.82, a current ratio of 4.70 and a debt-to-equity ratio of 0.74. Establishment Labs Holdings Inc. has a fifty-two week low of $17.69 and a fifty-two week high of $88.66. The business has a 50-day moving average of $71.65 and a 200-day moving average of $73.71.
Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, July 29th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. Establishment Labs had a negative net margin of 19.78% and a negative return on equity of 29.92%. The company had revenue of $31.99 million for the quarter, compared to analyst estimates of $31.50 million. As a group, sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -1.14 EPS for the current fiscal year.
Establishment Labs Profile
Establishment Labs Holdings, Inc is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It operates through the following geographical segments: Europe, Latin America, Asia Pacific and Middle East, and Other. The firm’s products include Motiva Implants, Motiva Flora Tissue Expander, Divina, and Puregraft.
Recommended Story: What is the definition of a trade war?
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.